Eli Lilly: promising data on lebrikizumab


(CercleFinance.com) – Eli Lilly announces that a phase III trial has demonstrated the potential of lebrikizumab, a new monoclonal antibody inhibitor of IL-13, when combined with topical corticosteroids (TCS ), in people with moderate to severe atopic dermatitis (AD).

At week 16, the study met all primary endpoints (skin clarity and severity rating) and key secondary endpoints (skin improvement, relief of itching, and improvement of itch-to-skin interference. sleep and quality of life).

“These results support the hypothesis that targeting IL-13 is essential for treating AD and helping to improve outcomes for these patients,” said in substance Lotus Mallbris, vice president at Eli Lilly.

‘We look forward to continuing to assess the clinical utility of lebrikizumab in ongoing studies with the hope of making this drug available to those who still have unmet needs,’ he concluded.

Copyright © 2021 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.

Facebook
Linkedin
E-mail





Source link -85